PT-141 in the intranasal format much of its original research used.
- Contains
- PT-141 (sequence, formula and CAS number are on the vial product page)
- Content
- 15mg in a metered 15ml bottle
- Presentation
- ready-to-use metered intranasal solution; no reconstitution step
- Purity
- ≥99% by HPLC, identity confirmed by mass spectrometry
- Released against
- the Certificate of Analysis for its own batch
About PT-141 Nasal Spray
This supplies PT-141, the MC4R-weighted cyclic melanocortin agonist, in solution in a metered 15ml intranasal bottle.
The intranasal route is the one a good deal of the early work on this compound employed, so the presentation aligns a study with the published method. The compound itself is identical to the vial preparation.
What the research covers
Research context is unchanged: central MC4R signalling, arousal and appetite endpoints, with the haemodynamic observations characteristic of melanocortin agonism as a secondary consideration.
Concentration is fixed, which suits consistency across sessions and does not suit dose-ranging. The PT-141 page covers the pharmacology and the distinction from its parent compound. The sexual health research peptides hub sets out the two ends of the axis this group spans.
Handling PT-141 Nasal Spray
Supplied as a metered preparation, so there is no reconstitution step and no reconstitution error, and no opportunity to set the concentration.
Store cold, upright and away from light. A peptide already in solution has a shorter usable life than a sealed lyophilised vial; this format trades shelf stability for immediate usability.
Other formats
The same compound is supplied as a lyophilised PT-141 vial, which gives control over concentration that a fixed solution cannot.
Common questions about PT-141 Nasal Spray
Is this the same compound as the PT-141 vial?
Yes. The compound is identical; it is supplied already in solution in a metered intranasal bottle instead of as a lyophilised powder.
When is the nasal spray the better choice?
When the intranasal route is itself part of the study design, or when consistency between sessions matters more than control over concentration.
When is the vial the better choice?
When the protocol needs to set its own concentration or run dose-ranging. A fixed-concentration solution cannot be varied.
How long does the spray remain usable?
A peptide in solution has a shorter usable life than a sealed lyophilised vial. Keep the bottle cold, upright and protected from light, and treat its life as limited.
